Dr A. Saul

Allan Saul

Novartis Vaccines Institute for Global Health, Italy

Allan Saul was appointed to establish then direct the Novartis Vaccines Institute for Global Health (NVGH) in September 2007.  This Institute is co-located in Siena Italy with the major research and development facility of Novartis Vaccines and Diagnostics.  NVGH has a mission to develop effective and affordable vaccines for neglected diseases of impoverished countries and provides a conduit for the application of Industrial vaccine development know how and resources to the translational research required to take vaccines specifically designed for the third world from laboratory concept though pilot scale production to proof of concept in humans.

Prior to joining NVGH, Dr Saul has more than 25 years experience working on the development and testing of experimental malaria vaccines, field work in epidemiology and testing control programs for malaria in endemic countries and in laboratory based research in antigen identification and characterization of potential protective immune responses.  He held previous appointments at the National Institutes of Health (USA) where he was the co-branch chief of the Malaria Vaccine Development Branch and at the Queensland Institute of Medical Research (Brisbane, Australia).

Dr Saul was trained in Biochemistry at the University of Queensland, Australia.  During his time at the Queensland Institute of Medical Research (QIMR) he worked on the biology of malaria, and on the development and testing of malaria vaccines.  During his period at both QIMR and the NIH, he oversaw the production of many malaria antigens for human clinical trials, characterization of new adjuvants including human studies with novel adjuvants.  He has been part of many malaria vaccine trials in Australia, USA, Switzerland, PNG and Africa.  These studies included two phase 2 trials in endemic countries: a triple combination of blood stage antigens in Papua New Guinea and a Phase 2 study of AMA1 in Mali. During this time, as a Professor in the joint QIMR/University of Queensland, Australian Centre for Tropical Health and Nutrition, he worked on malaria control programs in many countries in Asia, including a major program to develop sustainable, community based control programs in the Philippines.  
More recently, as the first Director of NVGH, he has overseen the development of a new institute with a growing pipeline of vaccines targeting developing world diseases. A major milestone has been its first vaccine trials: conjugate vaccines for Salmonella Typhi tested in Europe, Pakistan, India and The Philippines with several other vaccines soon to go into trials.